Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06882961 in Japanese Adults With Type 2 Diabetes Mellitus [Phase 1]

View source ↗

Summary

Phase 1 study assessing safety, tolerability, PK, and PD of PF-06882961 in Japanese adults with Type 2 Diabetes Mellitus completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• PF-06882961

Snippet

Sponsor: Pfizer | Conditions: Type 2 Diabetes Mellitus | Phase 1 | Status: COMPLETED | Results posted: 2022-03-11